Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

View Full Paper
Ask AI
Bookmark
Share

Authors

YGYan GaoLPLiqin PingYHYunhong Huang

Discussion

Loading...

Member takes

Overview

RIPPLE trial demonstrates 71.9% overall response rate in untreated indolent B-cell lymphoma, indicating effective immunotherapy option.

Key Points

  • Complete response rate was 56.1% among 57 treatment-naïve patients assessed at 5 years.
  • Overall progression-free survival and overall survival rates were 60.5% and 91.2%, respectively, at the median follow-up.
  • Induction therapy included rituximab biosimilar and pegylated interferon α-2b every 21 days for 6 cycles.
  • Results suggest potential benefits of coupled pegylated interferon α-2b and entecavir in patients with chronic hepatitis B co-infection.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dffdhttps://doi.org/10.1182/blood-2025-5375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study  FIL_RI-CHOP2025
  2. 2Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up2025 · 2 citations
  3. 3B cell and anti-PLA2R antibody-guided rituximab therapy in idiopathic membranous nephropathy: a prospective multi-center cohort study in the East Coastal Region of China2025
  4. 4Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL2025
  5. 5Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma2026